Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation - 04/03/22
, M.M. van Leeuwen b , H.S. Lau c , A. Ten Brinke d , L.E. Visser b, e, f , E.M. de Koning c , G.J. Braunstahl g, h Abstract |
The anti-IL-5 biologic reslizumab for the treatment of severe eosinophilic asthma is administered intravenously. In the current study home administration of intravenous reslizumab was evaluated in 24 patients included between 2019 (July) and 2020 (July). This is the first study to show that intravenous reslizumab can be administered safely and successfully in an outpatient setting. Notably, not all patients prefer home administration and severe asthma patients may have different needs when it comes to choosing treatment at home or in the hospital.
Le texte complet de cet article est disponible en PDF.Highlights |
• | The worldwide COVID-19 pandemic urges us to speed up implementation of home treatment for chronic diseases such as severe asthma. |
• | Intravenous reslizumab can be administered safely and successfully in an outpatient setting. |
• | Patients with severe asthma have different needs when it comes to choosing in-hospital or home treatment with biologics. |
Keywords : Severe asthma, Home administration, Biologics
Abbreviations : IM, IV, SC, HA, IL, ACQ, SEA, SA, AQLQ, ATS, ERS
Plan
Vol 194
Article 106776- avril 2022 Retour au numéro
Article précédent
- A prospective study of switching asthma patients from a Fixed-Dose Combination (FDC) Inhaled Corticosteroid [ICS]/Long-Acting Beta Agonist [LABA] therapy delivered by Dry Powder Inhaler (DPI) to ICS/LABA delivered by pressurised Metered Dose Inhaler (pMDI)
- Mona Al-Ahmad, David Webb
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?